Association between Use of HMG CoA Reductase Inhibitors and Mortality in HIV-Infected Patients

Moore, Richard D.; Bartlett, John G.; Gallant, Joel E.
July 2011
PLoS ONE;2011, Vol. 6 Issue 7, p1
Academic Journal
Introduction: HIV infection is a disease associated with chronic inflammation and immune activation. Antiretroviral therapy reduces inflammation, but not to levels in comparable HIV-negative individuals. The HMG-coenzyme A reductase inhibitors (statins) inhibit several pro-inflammatory processes and suppress immune activation, and are a logical therapy to assess for a possible salutary effect on HIV disease progression and outcomes. Methods: Eligible patients were patients enrolled in the Johns Hopkins HIV Clinical Cohort who achieved virologic suppression within 180 days of starting a new highly active antiretroviral therapy (HAART) regimen after January 1, 1998. Assessment was continued until death in patients who maintained a virologic suppression, with right-censoring of their follow-up time if they had an HIV RNA >500 copies/ml. Cox proportional hazards regression was used to assess statin use as a time-varying covariate, as well as other demographic and clinical factors. Results: A total of 1538 HIV-infected patients fulfilled eligibility criteria, of whom 238 (15.5%) received a statin while taking HAART. There were 85 deaths (7 in statin users, 78 in non-users). By multivariate Cox regression, statin use was associated with a relative hazard of 0.33 (95% CI: 0.14, 0.76; P = 0.009) after adjusting for CD4, HIV-1 RNA, hemoglobin and cholesterol levels at the start of HAART, age, race, HIV risk group, prior use of ART, year of HAART start, NNRTI vs. PI-based ART, prior AIDS-defining illness, and viral hepatitis coinfection. Malignancy, non-AIDS-defining infection and liver failure were particularly prominent causes of death. Discussion: Statin use was associated with significantly lower hazard of dying in these HIV-infected patients who were being effectively treated with HAART as determined by virologic suppression. Our results suggest the need for confirmation in other observational cohorts, and if confirmed, the need for a clinical trial of statin use in HIV infection.


Related Articles

  • Dysregulated Immune Activation in Second-Line HAART HIV+ Patients Is Similar to That of Untreated Patients. Espíndola, Milena S.; Lima, Leonardo J. G.; Soares, Luana S.; Cacemiro, Maira C.; Zambuzi, Fabiana A.; de Souza Gomes, Matheus; Amaral, Laurence R.; Bollela, Valdes R.; Martins-Filho, Olindo A.; Frantz, Fabiani G. // PLoS ONE;12/18/2015, Vol. 10 Issue 12, p1 

    Background: Successful highly active antiretroviral therapy (HAART) has changed the outcome of AIDS patients worldwide because the complete suppression of viremia improves health and prolongs life expectancy of HIV-1+ patients. However, little attention has been given to the immunological...

  • Low-Level Viremia and Proviral DNA Impede Immune Reconstitution in HIV-1--Infected Patients Receiving Highly Active Antiretroviral Therapy. Ostrowski, Sisse R.; Katzenstein, Terese L.; Thim, Per T.; Pedersen, Bente K.; Gerstoft, Jan; Ullum, Henrik // Journal of Infectious Diseases;2/1/2005, Vol. 191 Issue 3, p348 

    Background. Immunological and virological consequences of low-level viremia in human immunodeficiency virus (HIV) type 1-infected patients receiving highly active antiretroviral therapy (HAART) remain to be determined. Methods. For 24 months, 101 HAART-treated, HIV-1-infected patients with HIV...

  • Targeting platelet-derived soluble CD40 ligand: a new treatment strategy for HIV-associated neuroinflammation? Davidson, Donna C.; ackson, Joseph W.; Maggirwar, Sanjay B. // Journal of Neuroinflammation;2013, Vol. 10 Issue 1, p1 

    Human immunodeficiency virus type 1 (HIV) continues to be one of the most prevalent global health afflictions to date. The advent and introduction of combined antiretroviral therapy (cART) has made a significant impact on the course of infection. However, as patients are living longer, many...

  • Inflammation and Complications of HIV Disease. Dubé, Michael P.; Sattler, Fred R. // Journal of Infectious Diseases;6/15/2010, Vol. 201 Issue 12, p1783 

    In this article the author discusses the complications of chronic HIV infection. He is critical on the elevated levels of biomarkers representing an important potential explanatory variable to understand the increased incidence of complications related to chronic inflammation among HIV-infected...

  • Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis. Price, Huw; Dunn, David; Pillay, Deenan; Bani-Sadr, Firouze; de Vries-Sluijs, Theodora; Jain, Mamta K.; Kuzushita, Noriyoshi; Mauss, Stefan; Núñez, Marina; Nüesch, Reto; Peters, Marion; Reiberger, Thomas; Stephan, Christoph; Tan, Lionel; Gilson, Richard // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Background: Hepatitis B coinfection is common in HIV-positive individuals and as antiretroviral therapy has made death due to AIDS less common, hepatitis has become increasingly important. Several drugs are available to treat hepatitis B. The most potent and the one with the lowest risk of...

  • Body Mass Index and CD4+ T-Lymphocyte Recovery in HIV-Infected Men with Viral Suppression on Antiretroviral Therapy. Palermo, Brandon; Bosch, Ronald J.; Bennett, Kara; Jacobson, Jeffrey M. // HIV Clinical Trials;Jul/Aug2011, Vol. 12 Issue 4, p222 

    Purpose: To better characterize the relationship between body mass index (BMI) and CD4+ T-lymphocyte recovery in HIV disease.Methods: We analyzed the association between baseline BMI and CD4+ T-lymphocyte increases, as well as the association between BMI and immune activation (CD38 and HLA-DR...

  • HIV and Accelerated Atheroprogression: Role of Antiretroviral Therapy. Di Biagio, Antonio; Del Bono, Valerio; Rosso, Raffaella; Viscoli, Claudio // Current Pharmaceutical Biotechnology;Jan2012, Vol. 13 Issue 1, p88 

    The introduction of effective and potent treatments for human immunodeficiency virus (HIV) infection resulted in prolonged survival and better quality of life of HIV-infected patients. However, the longer survival and the anti-HIV medication side effects caused the emergence of new clinical...

  • Mortality and Morbidity of HIV Infected Patients Receiving HAART: A Cohort Study. Panos, George; Samonis, George; Alexiou, Vangelis G.; Kavarnou, Garyfallia A.; Charatsis, Gerasimos; Falagas, Matthew E. // Current HIV Research;May2008, Vol. 6 Issue 3, p257 

    HAART has substantially decreased mortality and morbidity among HIV-infected patients. We retrospectively analyzed morbidity and mortality in a cohort of HIV-infected adult patients with prolonged and frequent follow up (1987-2006). The study was divided in pre-HAART and HAART period for...

  • Modelling T4 cell count as a marker of HIV progression in the absence of any defense mechanism. Yadavalli, Venkata S. Sarma; Labeodan, Moremi Morire OreOluwapo; Udayabaskaran, Swaminathan; Forche, N. // Orion;2010, Vol. 26 Issue 2, p113 

    The T4 cell count, which is considered one of the markers of disease progression in an HIV infected individual, is modelled in this paper. The World Health Organisation has recently advocated that countries encourage HIV infected individuals to commence antiretroviral treatments once their T4...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics